Newsletter of the national gaucher foundation; summer, 2000
Gaucher Disease Newsletter Summer, 2000 A Publication of the National Gaucher Foundation Founded by Rubin Bakin Dear Doctor Q: I am a 35 year old woman who was diagnosed 10 years ago with Gaucher Disease. I have received ERT for 5 years and I feel great. I am going to Israel for 3 months. Can I stop my infusions while I am in Israel? A: There are various theories about this. I can tell you that there is a definite “reservoir” effect that takes place. During the three months, if you do not take enzyme, there will be a slow build up of glucocerebroside, but if you begin right after returning, it is likely that you will not suffer any negative effects. It is also possible to continue your therapy in Israel. Contact Dr. Ari Zimran, Director of the Shaare Zedek Gaucher Clinic at 972-2-655-5111 to discuss treatment options with him.
Q: My son is 18 months old and has Type 1 Gaucher Disease. He will start treatment soon. I am curious about the effect Gaucher has (if any) on the immune system. This is the second time he has been on Augmentin and it takes at least a week or two before he gets back to normal after finishing the medication. He has terrible diarrhea each time. I know that this is a side effect of the antibiotic, but it seems abnormal for it to continue to affect him so long after finishing the Augmentin. A: It is unlikely that your son’s infections are related to Gaucher Disease. He is probably allergic to something he is eating. Swollen tissues from allergic reactions frequently become “infected” due to lack of healthy drainage. The diarrhea is related to the amoxcillin. Give him ¼ teaspoon of powdered acidophilus in water twice daily for two weeks to replace the normal intestinal bacteria. This should eliminate the diarrhea. Please feel free to email me his normal week’s diet and I will
Lenny’s Legal Lines – Q & A By Lenny Van Pelt, Founder and Director of the International Patient Advocacy Association Q: I have been reading a lot about genetic privacy. As an individual with Gaucher, is informed consent a state requirement? A: Medical information is presumed confidential, but increasing capabilities to store and rapidly transfer data escalate the challenge of protecting privacy. Laws in many states restrict access to medical records. At issue is whether genetic information should be protected generally, as another component of individual medical records, or by specific genetic privacy laws. Laws in 13 states require individual informed consent to perform a genetic test or obtain genetic information. Nineteen states require consent to disclose genetic information. Colorado, Florida, Georgia, Louisiana, and Oregon explicitly define genetic information as personal property. Pending federal action may set minimum standards or preempt state laws on medical record privacy.
Q: I read an article you wrote regarding senior advocacy. The research about prescription usage and errors was shocking. Does this apply to Gaucher seniors? A: No…Advocacy for seniors with Gaucher has always been strong due to the support of the National Gaucher Foundation, Genzyme’s Reimbursement Dept., and the IPAA. Due to patient meetings, newsletters, etc., a senior is more informed and can avoid prescription errors you read about. For our readers, the research found 25% of all hospital and nursing home admissions result from seniors who do not take their medications properly. By the end of this year, there will be 35 million U.S. seniors who will take more than half of all prescriptions dispensed.
How to reach the IPAA: Office: 425-402-4037; Facsimile: 425-462-9532 Letters to the Editor Dear Friends, Every year, at Holiday time, members of the extended Cleverdon family create a small family fund. We do this to honor the spirit of the season as well as the memory of David W. Cleverdon. We all called him Grampa and remember his quiet passion, his abiding sense of justice, compassion and fair play. We each contribute a modest amount to the fund while one of us chooses a cause or organization to receive its proceeds. This choice reflects a specific concern of the chooser as well as the general interests of the entire family. This year, David Booth chose the National Gaucher Foundation. Joshua Booth, Grampa's first great grandchild and David's son, has Gaucher Disease. We all pray that during Joshua's lifetime a cure will be found for this disease. I cannot tell you how grateful we are that the National Gaucher Foundation exists -to promote research to discover treatments and a cure as well as to help patients and their families deal with the disease on a day to day basis. On behalf of the Cleverdon family, I am glad to be able to send you this contribution to further your good work. Peace and Godspeed, D. Cleverdon
Dear NGF: I have enclosed a $35 check to cover my membership fee. I was a member many years ago under the name of Michelle Jones. I have moved and married since that time. I am on Cerezyme and I am living an active life. What your Foundation does is absolutely wonderful. I don’t think I would have had such a wonderful life without the work of your Foundation. Thank you, Michelle
Dear NGF: I’d like to thank you for assisting me in my project. I received the materials on Monday and I’m very happy with both their quality and their visual appeal. You were a tremendous help to me. I only wish that there were more kind and helpful people like you out there. Thank you again. Sincerely, The Gendisease-J Listserv Discussion By Samuel Shponka Making full use of the technology revolution, those of us in the Gaucher community can now rapidly share information and feel less isolated. We have available to us a free, automated, e-mail program known as a listserv. E-mail sent to the listserv by a subscriber (someone on the listserv’s mailing list) is automatically sent to every other subscriber on that listserv, and delivered as ordinary e-mail. Thousands of listservs covering a wide range of topics exist, some with only a few subscribers and some with well over ten thousand subscribers. In 1994, Wayne Rosenfield started a listserv for people who have Gaucher Disease or one of the other rare inherited metabolic diseases disproportionately affecting people of Jewish descent. Gendisease-J, as the new discussion was called, now has well over two hundred subscribers throughout the world. It includes people with Gaucher Disease, family members, doctors, nurses, researchers and others interested in Gaucher Disease or other inherited metabolic disorders. It’s accessible twenty-four hours a day and it’s independent in that neither Genzyme nor NGF controls its contents. In fact, the participants themselves determine the content, with occasional input from the Gendisease-J listserv discussion. On this discussion list: We get important Gaucher news faster than any other way. In 1997, when black specks were found in my shipment of Cerezyme®, I notified Genzyme and then posted the report to the listserv. This was the only place where we could have shared information so rapidly about the specks, Genzyme’s response, and what we needed to do. We learned it was important to prevent the enzyme from foaming while preparing it for infusion because foaming could cause it to degrade. We found out about plans for the 1998 Gaucher conference in Memphis and the 1999 Gaucher conference in Arlington, long before we heard about it from any other source. If not for this listserv, it would have been almost impossible for the Gaucher Conference Committee, an independent organization not connected with either Genzyme or NGF, to put on these conferences. We read about Gaucher treatments under development by companies other than Genzyme. We can get advice and support from people living with Gaucher Disease and can offer others our support. We have read about people who, thanks to what they learned here, avoided unnecessary surgery urged on them by doctors who had limited experience with Gaucher Disease. We have been able to share and compare experiences with other members of our worldwide community on a daily basis, without regard for the miles that separate us. Many top doctors and researchers in Gaucher Disease are on this listserv. Their expertise is confirmed by years of experience treating hundreds of people who have Gaucher Disease and by their extensive research and numerous publications on Gaucher Disease. By sharing in our day-to-day struggles and triumphs, they become even more attuned to our needs, and become even better providers. The privacy of individual participants is respected here. Most of the over two hundred subscribers to the listserv just read the postings and never post anything themselves. Unless you post a message to the listserv, no one except Wayne will know you subscribe. You don’t have to worry about computer viruses either, because messages long enough to carry viruses as well as all types of attachments are rejected by the listserver. We are fortunate to have a resource like the Gendisease-J listserv, and the connection it provides to us as a worldwide community. This listserv is a blessing to the Gaucher community and to those involved with the other genetic diseases represented there.
EARLY RESEARCH ON ORAL THERAPY HOLDS PROMISE By Deborah Elstein and Ari Zimran, M.D., Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Gaucher disease, the most common glycolipid lysosomal storage disorder, is especially prevalent among Ashkenazi Jews, and hence, of importance in Israel. It has become a model for other inherited disorders particularly since effective enzyme replacement therapy has been introduced. Indeed, the enzymatic treatment has revolutionized the management of symptomatic patients; it leads to reduction of massive organomegaly, improvement in hypersplenism, and often amelioration of bone pain. However, the administration of the enzyme poses a significant hardship to the patient as it involves intravenous infusions, usually once every 2 weeks, for life. In addition, the high cost of enzyme treatment (between $100,000 to $400,000 per year of treatment for a 70 Kg adult patient, depending on the dosage regimen) limits the number of patients that can avail themselves of this treatment worldwide. Too, the current formulation of enzyme replacement is incapable of crossing the blood brain barrier, thereby limiting its value to patients with neurological manifestations. It is in this context, that a group of scientists and physicians from 4 European centers [including Zimran and Elstein from Shaare-Zedek Medical Center in Jerusalem] have recently published the results of a new clinical trial using a novel oral substrate inhibitor (the imino sugar N-butyl-deoxynojirimycin; OGT-918), which inhibits glucosyltransferase, the first step in the biosynthesis of glycolipids. This biological rationale, the successful outcome in animal models, and the safety data from an earlier clinical trial involving 130 patients with HIV, have suggested OGT-918 as a suitable candidate for oral treatment of glycolipid storage disorders. The authors report the results of a one-year open-label trial, wherein 28 adult patients with symptomatic Gaucher disease were enrolled (7 patients were post-splenectomy). All patients were started on 100mg OGT-918, taken orally 3 times a day. The safety profile of the drug was good, with the only significant side effects being diarrhea and abdominal discomfort, which occurred in two thirds of the patients, but disappeared within the first few weeks of treatment. Two patients withdrew from the trial because of these side effects; 4 other patients withdrew at various points during the trial for reasons unrelated to adverse effects. The report mentions 2 of 21 patients who continued beyond 12 months, who developed a peripheral neuropathy, which was reversible with stopping the drug. The treatment resulted in a dramatic reduction in spleen and liver volumes, 19% and 12% respectively, which is comparable to that seen in patients on enzyme replacement therapy. Blood counts, including hemoglobin and platelets, as well as chitotriosidase levels, also improved during the course of the trial, albeit at a less satisfactory rate. Based on the safety and efficacy demonstrated in this study and after further clinical research, OGT-918 may become a viable treatment for symptomatic patients without severe hypersplenism or for those who have developed side effects with enzyme. In addition, since OGT-918 as a small molecule crosses the blood-brain barrier, it is a candidate drug for the neuronopathic forms of Gaucher disease and may be the harbinger of an effective treatment in other lysosomal storage disorders as well. Finally, the article implies that OGT-918 is the first generation of similar-acting compounds already being developed. MED.ED.NOTE: Further studies are in progress to investigate the peripheral neuropathy issue, to explore varying dosages, and to develop protocols utilizing Cerezyme and OGT-918 together for improved therapeutic gains and decreased costs.
YOUR ACHING BACK . HOW TO CHOOSE THE PROPER EXERCISE PROGRAM FOR YOU (Second article of a three part series) by Suzanne Krupskas Please refer to the Spring 2000 Newsletter for the first set of exercises. Before you begin any exercise program consult your physician first. Your exercise routine should be painfree. Find your painfree position either in a sitting or standing position. Are you more comfortable in an arched position (called lordosis) or are you more comfortable bent slightly flattening the lower back (called kyphosis)? Arching your back is considered extension bias and flattening your low back is considered flexion bias. You always want to exercise within your painfree range. So find your most comfortable bias position and follow these guidelines. First, warm your back with a heating pad (preferably moist). The temperature should be gentle warmth - not too hot! Positioning is important so go by these guidelines: A) Flexion bias warmup - (AN ALTERNATIVE POSITION TO LYING ON YOUR BACK . see previous newsletter) Lie on your painfree side with 1-2 pillows under your head and 1-2 pillows between your legs. Place the heating pad on your back . rest comfortably for 15-20 minutes. B) Extension bias warmup - Lie on your stomach with a pillow under your stomach/pelvis area and a pillow under your shins. Place the heating pad on your lower back.rest comfortably for 15-20 minutes. After the warmup, perform the following exercises that are appropriate for your bias. You may want to exercise on the floor or the bed. If you choose the floor, make certain you are capable of getting on & off the floor without assistance and without any pain or strain. Throughout your exercise routine proper breathing is so important. Always exhale through your mouth during the exerting part of the exercise and inhale through your nose during the relaxation. The following flexion and extension bias exercises will ultimately strengthen the trunk stabilizers (stomach and back muscles). FLEXION BIAS EXERCISES: 1) Pelvic Tilt: (this exercise is repetitive from the first series, but so important) Lie on your back with yours knees bent. Tighten your stomach as you squeeze the buttocks, flattening your lower back into the bed or floor. Hold position for 3 seconds - 10-20 repetitions. 2) Alternate Arm Raise: (use 1-3 lb. arm weights, the weight should feel comfortable - Not Too Heavy) Holding the weights in each hand, perform a pelvic tilt first (see above exercise). Maintain the tilt, keep the elbows straight and palms down. Raise 1 arm up towards the ceiling (90 degrees from starting position), then lower and relax the tilt. Alternate arms and always perform the tilt first. 10-20 repetitions for each arm 3) Both Arm Raise: (use 1-3 1b. arm weights) Hold the weights in each hand. Keep your elbows straight and palms down. Perform the tilt and maintain it as you raise both arms towards the ceiling (90 degrees from the starting position), then lower the arms. Relax the pelvis and repeat 10-20 repetitions.
4) Touch Opposite Knee: (use 1-3 1b. weights for arms & legs) Same position as above with your arms by your sides. Perform a pelvic tilt and maintain the tilt. Slowly bring your right knee towards the chest as your left hand (with the weight) touches the knee. Bring the same arm up towards the ceiling simultaneously as you straighten the leg (parallel to the floor). Do not thrust the leg as the movement is very gentle. Perform 10 times on both sides. EXTENSION BIAS EXERCISES 1) Prop on Elbows: Lie on your stomach, place your elbows under your shoulders so that you are leaning on your forearms. In this position relax your low back muscles and breath naturally. Remain in this position for 3-4 minutes. 2) Press-Ups: (this exercise is repetitive from the First Series, but so important) Lie on your stomach with your palms down, with your elbows bent 90 degrees. Arms are shoulder width apart. Straighten your elbows as you press your palms into the bed or floor. Sink your pelvis into the bed or floor and hold position for 3 seconds then lower yourself as your face goes towards the bed/floor. Rest and perform 10-20 repetitions. 3) Buttock Squeeze: (use1-3 lb. ankle weights) Lie on your stomach, resting your head in your arms. Legs are together. Squeeze your buttocks together, as you bend your knees approximately 20 degrees off the bed/floor. Hold the position for 3 seconds then relax. Perform 10-20 repetitions. 4) Extension in Standing: Stand upright with your feet apart, knees are straight, place your hands in the small of your back. Bend your trunk backward at the waist as far as you can using your hands as a fulcrum. Hold position for 3 seconds. Perform 10-20 repetitions. This entire exercise regimen (first and second series) should be performed 4-5 times per week. Do not give up on these exercises as they are advantageous in preparing your body for daily activities. The third series will discuss ways to interlude both flexion and extension exercises into your exercise program. Good Luck! Here's to a healthier back! (This article is written by Suzanne L. Krupskas, a full-time Physical Therapist and Gaucher spokesperson. Any questions or comments, please contact Suzanne directly at:
Scoop on the Groups Chicago Chapter Please join the Chapter for their Second Annual Gaucher Disease Divot Classic on Thursday, July 20, 2000. The outing will be held at Midlane Golf Course in Wadsworth, Illinois. Various sponsorships are available. If you know of an individual, business or corporation who might be interested in participating, please call Cynthia Yannias at (847) 581-1855.
Delaware Valley Chapter The Fifth Annual Golf Fore Gaucher Disease Classic is scheduled for Friday, September 22, 2000 at Philmont Country Club in Philmont, PA. Save the date and plan to join us for big prizes, great food and drinks, and a fun-filled day of golf on one of the best courses in the area. Please call Larry Kaliner at (610) 649-6766 to reserve your spot!
Washington, DC Area Our national office is busy preparing for the First Union Golf Classic on Monday, August 7, 2000, at the Tournament Players Club at Avenel in Potomac, Maryland. We are very excited to have the support of such sponsors as First Union, Capital One, TheraCom, and Nova Factor. The golf invitations were mailed the beginning of June and registrations are rolling in! We hope to have a sold-out golf tournament again this year. If you would like to participate as a golfer, sponsor or volunteer, please call Sharon Adams at (800) 925-8885. We would greatly appreciate your support!
Tune In…. For readers in the NY City area, we would like to ask for your help. In an effort to educate the local community about Gaucher Disease, an NGF member has asked the NY television station, WNET, to run a segment on the disease. It appears that they determine programming based on the number of requests per month they receive on particular topics. We would like to ask our readers in the New York area to write a letter to the station requesting a segment on Gaucher Disease. We feel that if enough requests are submitted that there is a good chance the station will include an informational piece on Gaucher Disease. The contact information for WNET is, through the headquarters, at: NOVA-WGHB, 125 Western Avenue, Boston, MA 02134. We appreciate your help!
Special Appreciation The NGF would like to send a special Thank You to Claudia and Suzi Goodman for the wonderful arts and crafts fund-raiser they held this Spring. We realize that they donated their time and effort making the beautiful craft items that were sold. All the proceeds were given to the NGF for research and education on Gaucher Disease. We truly appreciate your help, Claudia and Suzi!
Click on Dr. Gaucher to return to the Gaucher Disease Homepage. 2000 by The National Gaucher Foundation Last Revised: August 12, 2000
INFORMACION PARA PRESCRIBIR AMPLIA Nombre Comercial: ANUAR ASF® Nombre Genérico: CABERGOLINA Forma Farmacéutica y Formulación: Comprimidos. Cabergolina. 0.5 mg Excipiente cbp…………………………………………………. 1 comprimido Indicaciones Terapéuticas: Inhibidor de la secreción de prolactina (PRL), Agonista dopaminérgico. ANUAR ASF
Rahmenhygieneplan für Alten- und Altenpflegeheime und weitere Einrichtungen nach § 1 Heimgesetz erarbeitet vom: Länder-Arbeitskreis zur Erstellung von Hygieneplänen nach § 36 IfSG Landesgesundheitsamt Brandenburg Landesamt für Gesundheit und Soziales Mecklenburg-Vorpommern Landesamt für Verbraucherschutz Sachsen-Anhalt Landesuntersuchungsanstalt für das Gesundheits-